Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma

Bone Marrow Transplantation

Volumn 36, Issue 4, 2005, Pages 315-323

  Neelapu, S S ^a   Munshi, N C ^b,e   Jagannath, S ^b,f   Watson, T M ^a   Pennington, R ^c   Reynolds, C ^d   Barlogie, B ^b   Kwak, L W ^a,g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f ST VINCENT S HOSPITAL MANHATTAN   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic; Donors; Idiotype; Immunization; Myeloma

Indexed keywords

BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; M PROTEIN; METHOTREXATE; THIOTEPA; TUMOR ANTIGEN; TUMOR VACCINE; VINCRISTINE;

ADULT; ALLOGRAFT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; ERYTHEMA; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; INJECTION SITE REACTION; KIDNEY FAILURE; MALE; MULTIPLE MYELOMA; ORGAN DONOR; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ISOLATION; SIBLING; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN IDIOTYPES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SIBLINGS; SURVIVAL RATE; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 23944475612     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705057     Document Type: Article

References (33)

1. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
2. Child JA, Morgan GJ, Davies FE et al. Medical Research Council Adult Leukemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
4. Attal M, Harousseau JL, Facon T et al. InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
5. Gahrton G, Svensson H, Cavo M et al. European Group for Blood and Marrow Transplantation. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216.
6. Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267-1273.
7. Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 2001; 38: 243-249.
8. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-1184.
9. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031-3037.
10. Hornung RL, Longo DL, Bowersox OC et al. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor. J Natl Cancer Inst 1995; 87: 1289-1296.
11. Kwak LW, Pennington R, Longo DL. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 1996; 87: 3053-3060.
12. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 1971; 68: 3130-3135.
13. Lynch RG, Graff RJ, Sirisinha S et al. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972; 69: 1540-1544.
14. Stevenson GT, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 1975; 254: 714-716.
15. Jorgensen T, Gaudernack G, Hannestad K. Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC-315. Scand J Immunol 1980; 11: 29-35.
16. Kwak LW, Campbell MJ, Zelenetz AD et al. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: Active immunization with tumor-derived idiotypic immunoglobulin. Blood 1990; 76: 2411-2417.
17. Kwak LW, Young HA, Pennington RW et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996; 93: 10972-10977.
18. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995; 345: 1016-1020.
19. Osterborg A, Yi Q, Henriksson L et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998; 91: 2459-2466.
20. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93: 2411-2419.
21. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999; 94: 673-683.
22. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Eng J Med 1992; 327: 1209-1215.
23. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remission induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171-1177.
24. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-58.
25. Li Y, Bendandi M, Deng Y et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 2000; 96: 2828-2833.
26. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001; 97: 1750-1755.
27. Lum LG, Seigneuret MC, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol 1986; 6: 389-396.
28. Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1: 339-343.
29. Kato S, Yabe H, Yabe M et al. Studies on transfer of varicella-zoster-virus specific T-cell immunity from bone marrow donor to recipient. Blood 1990; 75: 806-809.
30. Cabrera R, Diaz-Espada F, Barrios Y et al. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant 2000; 25: 1105-1108.
31. Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant 2005; 35 (Suppl. 1): S53-S57.
32. Maloney DG, Molina AJ, Sahebi F et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
33. Stevenson FK, Rice J, Ottensmeier CH et al. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 2004; 199: 156-180.